SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
SCNXCOMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - 10th, 2025.
Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
SCNXCommack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $3.9 million before deducting placement agent fees and other offering expenses. This offering is expected to close on August 15, 2025, subject to customary closing conditions.
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
SCNXCOMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL to its 3PL/Distribution Center for the intended commercial launch of the product. This shipment marks a major milestone accomplishment for Scienture, which has agreements in place for the distribution of the product through wholesalers and has received its first order for shipment in August 2025.
SCIENTURE Appoints Dr. Shankar Hariharan Co-CEO And executive Chairmen Of The Board And Appoints Dr. Narasimhan Mani President And Co-CEO
SCNXSCIENTURE Announces FDA Orange Book Patent Listing Arbli Oral Suspension, 10mg/mL
SCNXScienture Announces Manufacturing Launch Activities For Arbli Through Subsidiary Scienture, In Collaboration With Saptalis Pharmaceuticals And Strategic Distribution Partners, Targeting July 2025 Commercial Launch
SCNXSCIENTURE Announces Divestiture Of Its Legacy Healthcare IT And Wholesale Operations Subsidiaries To Tollo Health
SCNXScienture Holdings Releases Annual Letter To Shareholders
SCNXScienture Holdings Completes Equity Draw On Its Line Of Credit; Suspends Further Draws Until Reaching $10/Share Or 30 Trading Days
SCNXWhat's Going On With Scienture Shares Tuesday?
SCNXScienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company announced the FDA approved its new drug application for Arbli.
SCIENTURE Announces FDA Approval Of NDA For SCN-102, Being Developed By Subsidiary Scienture, LLC
SCNXScienture Holdings Appointed Eric Sherb As CFO
SCNXWhat's Going On With Scienture Stock Thursday?
SCNXScienture stock is trading higher on Thursday after the company partnered with Kindeva to launch REZENOPY.
Scienture Partners with Kindeva to Launch 10mg REZENOPY Nasal Spray for Opioid Overdose Treatment, Secures Exclusive US Rights to FDA-Approved Spray
SCNX